PMID

Data

Article Title

Organization

Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy.

Takeda California

Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors.

University of North Carolina At Chapel Hill

Synthesis, biological evaluation, and physicochemical property assessment of 4-substituted 2-phenylaminoquinazolines as Mer tyrosine kinase inhibitors.

Beijing Institute of Pharmacology & Toxicology

AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective.

University of Edinburgh

Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor.

Chinese Academy of Sciences (Cas)

Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase.

Chinese Academy of Sciences

Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).

Icahn School of Medicine At Mount Sinai

(R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors.

Genomics Institute of The Novartis Research Foundation

Design, Synthesis, and Biological Evaluation of Novel Imidazo[1,2-a]pyridine Derivatives as Potent c-Met Inhibitors.

Shanghai Institute of Materia Medica

Discovery and profiling of a selective and efficacious Syk inhibitor.

Novartis Institutes For Biomedical Research

UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.

University of North Carolina At Chapel Hill

Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases.

Chinese Academy of Sciences

Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.

Eshelman School of Pharmacy�Department of Pharmacology�Lineberger Compreh

Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors.

University of North Carolina At Chapel Hill

Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation.

Institut Curie

Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).

Exelixis

Highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase.

Pfizer

Design and synthesis of diarylamines and diarylethers as cytotoxic antitumor agents.

Beijing Institute of Pharmacology & Toxicology

Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK).

Glaxosmithkline

The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.

Amgen

Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.

Chinese Academy of Sciences

Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia.

TBA

Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.

TBA

Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.

Merck Research Laboratories

A quantitative analysis of kinase inhibitor selectivity.

Ambit Biosciences

Novel and selective spiroindoline-based inhibitors of Sky kinase.

Pfizer

Comprehensive analysis of kinase inhibitor selectivity.

Ambit Biosciences

Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.

Novartis Institute For Biomedical Research

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Ambit Biosciences

Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters.

University of Kentucky

Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy.

University of Illinois

Discovery of selective imidazole-based inhibitors of mammalian 15-lipoxygenase: highly potent against human enzyme within a cellular environment.

Bristol-Myers Squibb

Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1.

Karo Bio

Synthesis and Src kinase inhibitory activity of 2-phenyl- and 2-thienyl-7-phenylaminothieno[3,2-b]pyridine-6-carbonitriles.

Wyeth Research

Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity.

Biocryst Pharmaceuticals